Method for mitigating metastasis
AssigneesResearch Foundation of the City University of New York, Memorial Sloan Kettering Cancer Center, The General Hospital Corporation d/b/a Massachusetts General Hospital
InventorsJohn M. TARBELL, Lance L. MUNN, Henry QAZI, Zhongdong SHI
Life of this patent
Estimating the term…
Abstract
A method for inhibiting metastasis of cancer cells is provided. Inhibitors of heparan sulfate (HS) or hyaluronic acid (HA) are applied to a tumor or a surgical location after removal of the bulk of the tumor. The inhibitors enzymatically cleave surface HS or HA; genetically modify cancer cells to decrease HS or HA production or interfere with the signaling pathway between HS or HA and a MMP or syndecan.
Claims26
A method for inhibiting metastasis of cancer cells, method comprising steps of:
- treating an in vivo tumor with a heparan sulfate (HS) inhibitor wherein the heparan sulfate (HS) inhibitor causes a decrease in glycosaminoglycan concentration on a surface of cells in the in vivo tumor relative to untreated cells.
(canceled)
(canceled)
(canceled)
A method for inhibiting metastasis of cancer cells, the method comprising sequential steps of:
- surgically removing at least a portion of a tumor from an in vivo surgical location of a patient;
- treating the in vivo surgical location with heparan sulfate (HS) inhibitor wherein the heparan sulfate (HS) inhibitor causes a decrease in glycosaminoglycan concentration on a surface of cells in the in vivo surgical location relative to untreated cells, thereby inhibiting metastasis of any residual cancer cells in the in vivo surgical location.
(canceled)
(canceled)
(canceled)
(canceled)
A method for inhibiting metastasis of cancer cells, method comprising steps of:
- treating an in vivo tumor with a hyaluronic acid (HA) inhibitor wherein the hyaluronic acid (HA) inhibitor causes a decrease in glycosaminoglycan concentration on a surface of cells in the in vivo tumor relative to untreated cells;
- wherein the hyaluronic acid (HA) inhibitor is selected from a group consisting of:
- (a) a shRNA transfected into inactivate Hyaluronan synthase 1 (HAS1) gene, thus genetically modifying the in vivo tumor to decrease hyaluronic acid (HA) production;
- (b) a CRISPR-Cas9 transfected to inactivate HAS1 gene, thus genetically modifying the in vivo tumor to decrease hyaluronic acid (HA) production;
- and
- (c) a hyaluronidase, the hyaluronidase cleaving hyaluronic acid (HA) on the surface of the cells in the in vivo tumor.
Dependencies are inferred from the claim text.